Ignite Creation Date:
2024-05-06 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 12:51 PM
Study NCT ID:
NCT03631706
Status:
COMPLETED
Last Update Posted:
2024-02-26
First Post:
2018-08-09
Brief Title:
M7824 Versus Pembrolizumab as a First-line 1L Treatment in Participants With Programmed Death-ligand 1 PD-L1 Expressing Advanced Non-small Cell Lung Cancer NSCLC
Sponsor:
EMD Serono Research Development Institute Inc
Organization:
EMD Serono
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-10-01
Start Date Type:
ACTUAL
Primary Completion Date:
2021-06-07
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-06-30
Completion Date Type:
ESTIMATED
First Submit Date:
2018-08-09
First Submit QC Date:
August 13 2018
Study First Post Date:
2018-08-15
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
2022-06-29
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-07-18
Last Update Post Date:
2024-02-26
Last Update Post Date Type:
ACTUAL